Veracyte
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
- Total institutional ownership rose 6.0 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 118.51% +6.01pp
- Institutions
- 465 +15
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Marc Stapley | Chief Executive Officer | 0.20% |
| Robert Epstein | Independent Chairperson | 0.06% |
| Eliav Barr | Director and Member of Scientific & Technology Advisory Board | 0.06% |
| Rebecca Chambers | Chief Financial Officer | 0.04% |
| Muna Bhanji | Independent Director | 0.04% |
| Evan Jones | Independent Director | 0.04% |
| Phillip Febbo | Chief Scientific & Medical Officer | 0.03% |
| Jens Holstein | Independent Director | 0.03% |
| David Shafer | Independent Director | 0.02% |
| Thomas Miller | Director and Member of Scientific & Technology Advisory Board | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-27 | Jonathan Wygant | Vice President | Sale to Issuer | -1,306 | $50.31 |
| 2026-10-26 | Karin Eastham | Independent Director | Open Market Disposition | -4,850 | $50.00 |
| 2026-10-26 | Karin Eastham | Independent Director | Intent to Sell (Form 144) | -14,850 | $48.20 |
| 2026-10-26 | Karin Eastham | Independent Director | Derivative Exercise and Sale | -10,000 | $27.01–50.00 |
| 2026-10-26 | Jens Holstein | Independent Director | Derivative Exercise and Sale | -15,000 | $35.30–50.00 |
| 2026-10-26 | Jens Holstein | Independent Director | Intent to Sell (Form 144) | -7,500 | $50.00 |
| 2026-10-18 | Muna Bhanji | Independent Director | Automatic Disposition | -1,864 | $43.70 |
| 2026-09-23 | Jens Holstein | Independent Director | Intent to Sell (Form 144) | -7,500 | $47.00 |
| 2026-09-20 | John Leite | Global Chief Commercial Officer | Automatic Disposition | -4,015 | $40.00 |
| 2026-09-13 | Jens Holstein | Independent Director | Automatic Disposition | -5,000 | $40.95 |
| 2026-09-03 | Phillip Febbo | Chief Scientific & Medical Officer | Open Market Disposition | -13,110 | $42.89–43.66 |
| 2026-09-03 | Rebecca Chambers | Chief Financial Officer | Open Market Disposition | -3,652 | $42.81–43.71 |
| 2026-09-03 | Annie McGuire | Executive VP, General Counsel & Head of Market Access | Open Market Disposition | -3,254 | $42.79–43.67 |
| 2026-09-01 | Phillip Febbo | Chief Scientific & Medical Officer | Sale to Issuer | -3,639 | $44.88 |
| 2026-09-01 | Marc Stapley | Chief Executive Officer | Sale to Issuer | -8,782 | $44.88 |
| 2026-09-01 | Jonathan Wygant | Vice President | Sale to Issuer | -1,361 | $44.88 |
| 2026-09-01 | Rebecca Chambers | Chief Financial Officer | Sale to Issuer | -3,603 | $44.88 |
| 2026-09-01 | John Leite | Global Chief Commercial Officer | Sale to Issuer | -3,961 | $44.88 |
| 2026-09-01 | Annie McGuire | Executive VP, General Counsel & Head of Market Access | Sale to Issuer | -3,215 | $44.88 |
| 2026-08-31 | Muna Bhanji | Independent Director | Automatic Disposition | -1,864 | $42.97 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Veracyte discussion 0 comments